Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $4.05 and traded as high as $4.14. Oramed Pharmaceuticals shares last traded at $4.13, with a volume of 105,504 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ORMP. Weiss Ratings upgraded shares of Oramed Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Wall Street Zen downgraded shares of Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. One analyst has rated the stock with a Buy rating. Based on data from MarketBeat, the stock currently has an average rating of “Buy”.

Oramed Pharmaceuticals Stock Down 7.9%

The company has a market cap of $154.34 million, a price-to-earnings ratio of 0.90 and a beta of 1.31. The firm has a 50-day simple moving average of $4.38 and a 200 day simple moving average of $4.05.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its quarterly earnings data on Thursday, November 12th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.59). As a group, research analysts expect that Oramed Pharmaceuticals Inc. will post 1.47 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Avraham Gabay sold 20,000 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $4.51, for a total transaction of $90,200.00. Following the completion of the sale, the chief financial officer owned 861,076 shares in the company, valued at $3,883,452.76. This represents a 2.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joshua Hexter sold 30,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $135,300.00. Following the transaction, the chief operating officer directly owned 1,328,130 shares in the company, valued at $5,989,866.30. The trade was a 2.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ORMP. Bank of America Corp DE raised its holdings in shares of Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 3,909 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Oramed Pharmaceuticals by 5.1% during the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock worth $538,000 after buying an additional 7,738 shares during the last quarter. Engineers Gate Manager LP purchased a new position in shares of Oramed Pharmaceuticals during the second quarter worth about $61,000. BML Capital Management LLC grew its holdings in shares of Oramed Pharmaceuticals by 2.1% during the third quarter. BML Capital Management LLC now owns 884,392 shares of the biotechnology company’s stock worth $4,130,000 after buying an additional 18,123 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new position in Oramed Pharmaceuticals in the 1st quarter valued at about $63,000. 12.73% of the stock is currently owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.